Consiro Press · An imprint of Consiro Advisory, LLC

Books written from inside the room.

Boards are governing risks they were never trained for. Executives are deciding with incomplete information in domains where mistakes are expensive. Consiro Press publishes practitioners who have carried those decisions, and only when the field needs to hear what they have to say.

Cover of The Boardroom CISO by Antonio Bovoso

Now available

The Boardroom CISO

The Art of Translating Cyber Risk · Antonio Bovoso

#1 New Release in Corporate Governance on Amazon

Cybersecurity has a communication problem. Boards want to understand risk. CISOs want to be understood. The same conversation fails in the same ways in boardrooms across every industry: the technical is mistranslated, the stakes are misjudged, and the relationship that should be the organization’s strongest line of defense becomes one of its weakest.

This is a practitioner’s guide to closing that gap. It is a book about communication and trust, and about how security leaders earn a seat at the table and keep it.

Hardcover · Paperback · Kindle

Written for three readers

The CISOLearning to speak the language of the boardroom.
The board memberTrying to ask the right questions.
The executiveWho needs to stop treating cybersecurity as an IT problem.

The standard every title has to meet

Does this help a leader do something better tomorrow?

What gets published

Three conditions. All three have to hold.

Where strategy meets practice

Neither a technical manual nor management theory. The place where governance, strategy and practice have to meet, and usually do not.

Where misunderstanding is costly

Subjects where getting it wrong is expensive, public or both, and where a reader has little margin to work it out alone.

Written by someone who carried the decision

Experience in the room over theory about it. This is the condition that rules most books out.

About the author

Antonio Bovoso

A CISO with 25 years across Big 4 consulting, Fortune 500 enterprises and a CISO role at a publicly traded biopharmaceutical company.